STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against Regeneron Pharmaceuticals (REGN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Regeneron Pharma (REGN) PT Lowered to $1,120 at Jefferies
January 13, 2025 11:25 AM ESTJefferies analyst Akash Tewari lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,120.00 (from $1,200.00) while maintaining a Buy rating.
The analyst comments "REGN pre-announced Q4 #'s w/ US LD Eylea beat by ~$126m (12%) + HD miss by ~$111m (27%) & there's $85m inventory... More
